Cardiac Dimensions
Founded Year
2000Stage
Series D | AliveTotal Raised
$214.76MLast Raised
$35M | 1 yr agoAbout Cardiac Dimensions
Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. Its initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. The company was founded in 2000 and is based in Kirkland, Washington.
Loading...
Loading...
Cardiac Dimensions Patents
Cardiac Dimensions has filed 54 patents.
The 3 most popular patent topics include:
- cardiac anatomy
- cardiac surgery
- valvular heart disease
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/10/2021 | 3/7/2023 | Implants (medicine), Dosage forms, Drug delivery devices, Prosthetics, Medical equipment | Grant |
Application Date | 12/10/2021 |
|---|---|
Grant Date | 3/7/2023 |
Title | |
Related Topics | Implants (medicine), Dosage forms, Drug delivery devices, Prosthetics, Medical equipment |
Status | Grant |
Latest Cardiac Dimensions News
Apr 26, 2023
Cardiac Dimensions Receives Medical Device Regulation (MDR) Certification for Carillon Mitral Contour System The Carillon Mitral Contour System, is a groundbreaking, non-surgical, minimally invasive device developed to treat patients with mitral valve insufficiency The Carillon therapy preserves the integrity of the mitral valve to allow for other FMR treatments should they be needed. (Credit: jesse orrico on Unsplash) Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address patients suffering from heart failure with functional mitral regurgitation (FMR), today announced that its Carillon Mitral Contour System has received certification under Regulation (EU) 2017/745 (“MDR”). The MDR program is intended to ensure high standards of safety and quality of medical devices that are produced in, or supplied to, member countries of the EU. According to the most recent data published by the European Commission last December, fewer than 10% of products holding a certificate under the predecessor program, the Medical Devices Directive (MDD), had received MDR certification. “I am proud of our team, who committed significant time and resources to ensuring our device and systems achieved the new high standards set by the EU, ahead of many in our industry,” said Cardiac Dimensions CEO Rick Wypych. “The excellent safety profile of the Carillon device coupled with the significant body of high-quality evidence supporting the Carillon therapy were key factors in achieving MDR certification. This milestone signals to our physician partners and patients that they can be confident in the safety and manufacturing excellence of the Carillon system.” “The Carillon device has the unique ability to both improve FMR symptoms and remodel the heart. MDR certification of the Carillon Mitral Contour System will ensure continued and uninterrupted access to this evidence-based treatment option for heart failure patients with FMR in Europe,” said Prof. Klaus Witte, Chair of Cardiac Device Therapy, University of Aachen. Source: Company Press Release
Cardiac Dimensions Frequently Asked Questions (FAQ)
When was Cardiac Dimensions founded?
Cardiac Dimensions was founded in 2000.
Where is Cardiac Dimensions's headquarters?
Cardiac Dimensions's headquarters is located at 5540 Lake Washington Blvd. NE, Kirkland.
What is Cardiac Dimensions's latest funding round?
Cardiac Dimensions's latest funding round is Series D.
How much did Cardiac Dimensions raise?
Cardiac Dimensions raised a total of $214.76M.
Who are the investors of Cardiac Dimensions?
Investors of Cardiac Dimensions include Lumira Ventures, M.H. Carnegie & Co., Arboretum Ventures, EQT Life Sciences, Hostplus and 16 more.
Who are Cardiac Dimensions's competitors?
Competitors of Cardiac Dimensions include NeoChord, Ancora Heart, Mitralign, CardiAQ Valve Technologies, CardioKinetix and 7 more.
Loading...
Compare Cardiac Dimensions to Competitors
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.
Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure
Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.
Mitralign develops a catheter-based technology for percutaneous treatment of functional mitral regurgitation. It emulates surgical annuloplasty delivering a series of surgical implants directly into the mitral annulus by means of a catheter. The company was founded in 2004 and is based in Tewksbury, Massachusetts.
CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
Loading...